R-Pharm and Nacimbio established a joint venture

| By | Drug Manufacturing, Nacimbio, R-Pharm, Rostec

National Immunobiological Company, a part of Rostec Corporation, and R-Pharm, a Russian pharmaceutical company, signed an agreement to establish a joint venture for manufacturing antiretroviral medicines. The document was signed by Maryam Khubieva, the CEO of Nacimbio, and Vasily Ignatiev, the CEO of R-Pharm Group. The joint venture is established to manufacture and sell medicinal products for the treatment of HIV infection in Russia, and their marketing authorizations will be contributed by R-Pharm. The first medicines are expected to be produced by the end of 2017.

Maryam Khubieva, the CEO of Nacimbio, said, “Today, there is an acute need in increasing the share of affordable Russian-made ARV medicines in the total volume of procured drugs in order to expand the coverage of patients with the therapy. This joint project with R-Pharm, which has a great expertise in manufacturing ARV medicines, will allow the uninterrupted provision of efficient and affordable drugs to all those who need them.”

Vasily Ignatyev, CEO of R-Pharm Group, said, “Localizing the manufacturing of antiretroviral medicines in partnership with Russian companies is a strategic goal of R-Pharm. We have been working for a long time in this segment and accumulated extensive experience in developing and manufacturing safe and high-quality drugs. We believe that medicinal products produced together with Nacimbio will facilitate the access of patients to advanced therapy schemes.”